Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 1.00 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9285147 | 0.90 | LRRK2 (0.81) | LRRK2MAP3K14CYP1A2 | |
| SCHEMBL5021250 | 0.88 | LRRK2 (0.80) | LRRK2MAP3K14CYP1A2 | |
| SCHEMBL15528273 | 0.82 | LRRK2 (0.70) | LRRK2MAP3K14TTKIRAK4 | |
| SCHEMBL28580338 | 0.80 | LRRK2 (0.67) | LRRK2MAP3K14 | |
| SCHEMBL4537130 | 0.79 | LRRK2 (0.67) | LRRK2CYP1A2 | |
| SCHEMBL9284774 | 0.79 | LRRK2 (0.82) | LRRK2MAP3K14CYP1A2 | |
| SCHEMBL16469033 | 0.77 | LRRK2 (1.00) | LRRK2MAP3K14 | |
| SCHEMBL15528021 | 0.77 | LRRK2 (0.62) | LRRK2CYP1A2IRAK4 | |
| SCHEMBL4559112 | 0.76 | LRRK2 (0.61) | LRRK2CYP1A2 | |
| SCHEMBL10286423 | 0.76 | LRRK2 (0.72) | LRRK2MAP3K14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844652-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-03-13 | — | — | EP | claimed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | claimed |
| EP-2844652-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | claimed |
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (CA) | 2015-02-19 | — | — | US | claimed |
| WO-2013164321-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | claimed |
| EP-2844652-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2844652-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2844652-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (CA) | 2015-02-19 | — | — | US | disclosed |
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (CA) | 2015-02-19 | — | — | US | disclosed |
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (CA) | 2015-02-19 | — | — | US | disclosed |
| WO-2013164321-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885MAP3K14 160/4885CYP1A2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.